In pursuit of a blockbuster, Amgen and AstraZeneca score priority review for asthma drug tezepelumab

Amgen and AstraZeneca are one big step closer to realizing their blockbuster dreams for tezepelumab after the FDA granted a priority review for the asthma drug.

Despite the challenge of battling Regeneron and Sanofi’s Dupixent, tezepelumab has been pegged for peak sales of $2.5 billion. With AstraZeneca leading development,...

Click to view original post